Find Difamilast manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Opa-15406, 937782-05-3, Difamilast [usan], T3u32glj0f, N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide, Benzamide, n-((2-(4-(difluoromethoxy)-3-(1-methylethoxy)phenyl)-4-oxazolyl)methyl)-2-ethoxy-
Molecular Formula
C23H24F2N2O5
Molecular Weight
446.4  g/mol
InChI Key
VFBILHPIHUPBPZ-UHFFFAOYSA-N
FDA UNII
T3U32GLJ0F

Difamilast
Difamilast is under investigation in clinical trial NCT01702181 (A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis).
1 2D Structure

Difamilast

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide
2.1.2 InChI
InChI=1S/C23H24F2N2O5/c1-4-29-18-8-6-5-7-17(18)21(28)26-12-16-13-30-22(27-16)15-9-10-19(32-23(24)25)20(11-15)31-14(2)3/h5-11,13-14,23H,4,12H2,1-3H3,(H,26,28)
2.1.3 InChI Key
VFBILHPIHUPBPZ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCOC1=CC=CC=C1C(=O)NCC2=COC(=N2)C3=CC(=C(C=C3)OC(F)F)OC(C)C
2.2 Other Identifiers
2.2.1 UNII
T3U32GLJ0F
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Opa-15406

2.3.2 Depositor-Supplied Synonyms

1. Opa-15406

2. 937782-05-3

3. Difamilast [usan]

4. T3u32glj0f

5. N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide

6. Benzamide, N-((2-(4-(difluoromethoxy)-3-(1-methylethoxy)phenyl)-4-oxazolyl)methyl)-2-ethoxy-

7. Benzamide, N-[[2-[4-(difluoromethoxy)-3-(1-methylethoxy)phenyl]-4-oxazolyl]methyl]-2-ethoxy-

8. Mm36

9. Difamilast [inn]

10. Difamilast [jan]

11. Difamilast (jan/usan)

12. Unii-t3u32glj0f

13. Difamilast [who-dd]

14. Gtpl9776

15. Schembl4275421

16. Chembl3989968

17. Bdbm389126

18. Db14987

19. Usre46792, 352

20. Example 352 [wo2007058338]

21. Hy-109085

22. D11314

23. N-((2-(4-(difluoromethoxy)-3-isopropoxyphenyl)oxazol-4-yl)methyl)-2-ethoxybenzamide

24. N-[2-(4-difluoromethoxy-3-isopropoxyphenyl)oxazol-4-ylmethyl]-2-ethoxybenzamide

25. N-((2-(4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl)-1,3-oxazol-4-yl)methyl)-2-ethoxybenzamide

2.4 Create Date
2012-08-19
3 Chemical and Physical Properties
Molecular Weight 446.4 g/mol
Molecular Formula C23H24F2N2O5
XLogP34.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count8
Rotatable Bond Count10
Exact Mass446.16532819 g/mol
Monoisotopic Mass446.16532819 g/mol
Topological Polar Surface Area82.8 Ų
Heavy Atom Count32
Formal Charge0
Complexity583
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Difamilast

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content

Difamilast

About the Company : Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, ant...

Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, antibiotics, ARVs, CNS, and cardiovascular segments. The company operates facilities approved by US FDA, EDQM, Health Canada, and WHO-GMP, supported by multiple global DMFs and Ecovadis recognition. Backed by strong R&D, global patents, and customer-focused practices, Maithri delivers high-quality APIs with regulatory excellence. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

03

FandaChem

China
Sampe
Not Confirmed
arrow

FandaChem

China
arrow
Sampe
Not Confirmed

Difamilast

About the Company : FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a w...

FandaChem, headquartered in Hangzhou, China, is a reputable supplier and exporter of chemicals with a focus on delivering high-quality products. Our expertise lies in exporting a wide range of superior chemicals, specializing in areas such as agrochemicals, flavors, fragrances, pharmaceuticals, intermediates, paints, resins, plastics, surfactants, polymers, cosmetics, and more. Dedicated to being your dependable partner in China, FandaChem is devoted to offering top-notch products, competitive prices, and excellent service to meet the needs of our customers.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Difamilast is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 22, 2025

blank

01

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Difamilast is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 22, 2025

blank

Details:

Difamilast is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 15, 2025

blank

02

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Difamilast is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 15, 2025

blank

Details:

OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 28, 2022

blank

03

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 28, 2022

blank

Details:

OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 14, 2022

blank

04

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 14, 2022

blank

Details:

Difamilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 08, 2022

blank

05

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Difamilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 08, 2022

blank

Details:

Difamilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 07, 2022

blank

06

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Difamilast is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 07, 2022

blank

Details:

Moizerto (Difamilast) Ointment is a non-steroidal, topical phosphodiesterase type-4 inhibitor (commonly called a PDE4 inhibitor), improve the symptoms of atopic dermatitis.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Moizerto

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 01, 2022

blank

07

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Moizerto (Difamilast) Ointment is a non-steroidal, topical phosphodiesterase type-4 inhibitor (commonly called a PDE4 inhibitor), improve the symptoms of atopic dermatitis.

Product Name : Moizerto

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 01, 2022

blank

Details:

OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 13, 2022

blank

08

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : OPA-15406 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 13, 2022

blank

Details:

Moizerto Ointment (difamilast), in 1% and 0.3% formulations, is a non-steroidal topical phosphodiesterase type 4 inhibitor (PDE4 inhibitor). Moizerto Ointment was discovered by Otsuka in Tokushima Research Institute and is the first topical PDE4 inhibitor approved in Japan.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Moizerto

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 27, 2021

blank

09

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Moizerto Ointment (difamilast), in 1% and 0.3% formulations, is a non-steroidal topical phosphodiesterase type 4 inhibitor (PDE4 inhibitor). Moizerto Ointment was discovered by Otsuka in Tokushima Research Institute and is the first topical PDE4 inhibito...

Product Name : Moizerto

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 27, 2021

blank

Details:

Difamilast is a topical atopic dermatitis drug candidate discovered by Otsuka that has phosphodiesterase 4 (PDE4) inhibitory activity.


Lead Product(s): Difamilast,Inapplicable

Therapeutic Area: Dermatology Brand Name: Moizerto

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Medimetriks Pharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 28, 2020

blank

10

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Lead Product(s) : Difamilast,Inapplicable

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Medimetriks Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Difamilast is a topical atopic dermatitis drug candidate discovered by Otsuka that has phosphodiesterase 4 (PDE4) inhibitory activity.

Product Name : Moizerto

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 28, 2020

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

DIFAMILAST

Brand Name : ADQUEY

Dosage Form : OINTMENT;TOPICAL

Dosage Strength : 1%

Approval Date : 2026-02-12

Application Number : 219474

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Bioprocess International Europe
Not Confirmed
arrow
Bioprocess International Europe
Not Confirmed

DIFAMILAST

US Patent Number : RE46792

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 219474

Patent Use Code : U-4445

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-03-01

blank

02

arrow
Bioprocess International Europe
Not Confirmed
arrow
Bioprocess International Europe
Not Confirmed

DIFAMILAST

US Patent Number : 10588893

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 219474

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2036-12-31

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
Bioprocess International Europe
Not Confirmed
arrow
Bioprocess International Europe
Not Confirmed

DIFAMILAST

Exclusivity Code : NCE

Exclusivity Expiration Date : 2031-02-12

Application Number : 219474

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 937782-05-3 / Difamilast API manufacturers, exporters & distributors?

Difamilast manufacturers, exporters & distributors 1

52

PharmaCompass offers a list of Difamilast API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Difamilast manufacturer or Difamilast supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Difamilast manufacturer or Difamilast supplier.

API | Excipient name

Difamilast

Synonyms

Opa-15406, 937782-05-3, Difamilast [usan], T3u32glj0f, N-[[2-[4-(difluoromethoxy)-3-propan-2-yloxyphenyl]-1,3-oxazol-4-yl]methyl]-2-ethoxybenzamide, Benzamide, n-((2-(4-(difluoromethoxy)-3-(1-methylethoxy)phenyl)-4-oxazolyl)methyl)-2-ethoxy-

Cas Number

937782-05-3

Unique Ingredient Identifier (UNII)

T3U32GLJ0F

About Difamilast

Difamilast is under investigation in clinical trial NCT01702181 (A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis).

Difamilast Manufacturers

A Difamilast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Difamilast, including repackagers and relabelers. The FDA regulates Difamilast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Difamilast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Difamilast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Difamilast Suppliers

A Difamilast supplier is an individual or a company that provides Difamilast active pharmaceutical ingredient (API) or Difamilast finished formulations upon request. The Difamilast suppliers may include Difamilast API manufacturers, exporters, distributors and traders.

click here to find a list of Difamilast suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Difamilast USDMF

A Difamilast DMF (Drug Master File) is a document detailing the whole manufacturing process of Difamilast active pharmaceutical ingredient (API) in detail. Different forms of Difamilast DMFs exist exist since differing nations have different regulations, such as Difamilast USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Difamilast DMF submitted to regulatory agencies in the US is known as a USDMF. Difamilast USDMF includes data on Difamilast's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Difamilast USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Difamilast suppliers with USDMF on PharmaCompass.

Difamilast GMP

Difamilast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Difamilast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Difamilast GMP manufacturer or Difamilast GMP API supplier for your needs.

Difamilast CoA

A Difamilast CoA (Certificate of Analysis) is a formal document that attests to Difamilast's compliance with Difamilast specifications and serves as a tool for batch-level quality control.

Difamilast CoA mostly includes findings from lab analyses of a specific batch. For each Difamilast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Difamilast may be tested according to a variety of international standards, such as European Pharmacopoeia (Difamilast EP), Difamilast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Difamilast USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty